Tissue Regenix Share Discussion Threads

[rayrac] 20/1/2016 08:02

Warming up! Won't be ignored for much longer!!

[igbertsponk] 20/1/2016 08:02

Dropping bits of news like this is often the precursor of bigger news: rights issue perhaps?

[bamboo2] 20/1/2016 07:53

Ig, Cheers! Three news items in three days, what's going on?
Hopefully third time lucky for the share price

There's plenty of other activity going on in the background, eg,

"We are presenting a new technique which we have developed for the reconstruction of small to medium sized scalp defects using dCELL, a human dermis allograft. This technique has not yet been described in the current literature and offers a new possibility in the reconstruction of problem scalp defects."

hxxp://www.bjoms.com/article/S0266-4356%2815%2900549-5/abstract

Also attendance at various trade shows, symposia etc.

[igbertsponk] 20/1/2016 07:12

$1m sales. Woowee

[igbertsponk] 19/1/2016 08:41

He looks a good addition.

[bamboo2] 19/1/2016 07:57

Tissue Regenix Group strengthens Board with Non-Executive appointment

York, 19 January 2016 - Tissue Regenix Group plc (AIM:TRX) ("Tissue Regenix") or ("The Company") the regenerative medical devices company, is pleased to announce the appointment of Jonathan Glenn as a Non- Executive Director with immediate effect.

Jonathan has been Chief Executive Officer at Consort Medical plc since December 2007, having originally joined the company in September 2006 as Chief Financial Officer. Prior to joining Consort Medical, he held a number of senior financial roles across the medical industry including Akubio Ltd 2005- 2006 and the Celltech Group plc 1998-2005. He has a broad range of commercial experience across the medical devices industry, particularly with regard to clinical trial management and the US market place. During his time with Celltech he was pivotal in the acquisitions of Chiroscience, Medeva and OGS.

John Samuel, Chairman of Tissue Regenix Group said:

"We are very pleased to announce the appointment of Jonathan to the board.

He has excellent experience in the medical devices market and we look forward to working with him, we believe his appointment will strengthen the Board as we move into our next stage of development.

This is an exciting time for Tissue Regenix following the successful commercialisation of our woundcare products in the US, and the encouraging progress from the orthopaedic clinical trials in the EU, as well as the ongoing work in our cardiac applications"

Further Information:

Full name: Jonathan M Glenn

Age: 47

CORPORATE BOARDS

Consort Medical - Member of the Board and Chief Executive Officer

FORMER CORPORATE BOARDS

Akubio Ltd. (03/2005 - 09/2006)

Oxford Glyosciences (04/1997 - 08/1998)

[bamboo2] 18/1/2016 09:10

Hi Ig, yes, it is a bit of a shame the share price can't gain any traction at this level. I am slightly under my average again, but always intended to hold this one for the very long term, so not concerned.

The worry is that a low t/o could be of interest to the insti's, so we have to hope that management will be able to realise the forecast US Dermapure sales in the next set of figures, to keep them happy.

The recent fall is on small volume.

edit, Must add that it's a brilliant achievement to have helped at least 22 people with Orthopure meniscus or tendon repairs. These ops often occur in tandem, with surgeons normally having to harvest an autograft from elsewhere in the patient.

Orthopure siedsteps the second procedure, with its associated risks, and also reduces theatre time.

In order for the trial to be seen as successful we will have to at least match the current rate for meniscal repairs at 70%+. The success rate for ACL repair is around 85%. [US figs]

[igbertsponk] 18/1/2016 08:55

Even great news like this doesn't halt the slump !

[bamboo2] 18/1/2016 08:49

OrthoPure(TM) XM clinical trial enrolment completed

York, 18th January - Tissue Regenix Group plc (AIM:TRX) ("Tissue Regenix" or "The Group"), the regenerative medical devices company, announces it has now enrolled in its OrthoPure(TM) XM (porcine meniscus) clinical trial the 20 patients required to complete the submission for a CE mark in Europe.

With the final operation taking place in Valencia, Spain on Friday 12 January, the 20 patients are now required to be monitored for 6 months post-operation in order for the clinical trial to be accepted.

Tissue Regenix is undertaking a two part CE mark submission, which should ultimately reduce the time needed to process the application. The data from the clinical trial of these 20 patients is the final piece of information required to make the second part of the CE submission.

OrthoPure(TM) XM provides a biological repair for damaged menisci, a condition that can lead to the early onset of osteo-arthritis, and an injury for which treatments are currently limited. Tissue Regenix' Orthopaedics business has a specific focus on the orthopaedic sports injury market and is also in the process of undertaking clinical trials for a decellurised porcine tendon, OrthoPure(TM) XT, which began in December and is expected to be completed in the coming months.

Peter Hamer, Commercial Director of Orthopaedics at Tissue Regenix said "We are delighted to announce the completion of enrolment for the OrthoPure(TM) XM clinical trial. The strict selection criteria meant that there was only a small pool of patients which could be considered to validate the safety and success of the treatment. It is a testament to the hard work of both our research and development teams, and the clinical trial centres, that we have remained on course for CE mark submission by Q4 and hope to secure approval of the first of our dCELL(R) orthopaedic product by the end of the year"

[rayrac] 11/1/2016 08:27

Happy New Year to all...especially the 'grafters'!

[bamboo2] 02/1/2016 16:00

Hi mb, if you know of an artificial or biological alternative to human or porcine derived meniscus ECM, that is currently being used in human clinical trials, I'd really like to know please.

I have done extensive research this area, and as far as I know, the only viable transplant material is sourced from cadavers. The supply of usable human transplants is minute, hence the work by TRX to make xenografts and allografts an 'off the shelf' option.

Cadaver transplant material is relatively unprocessed, and carries potential risk for cross infection and rejection by the recipients immune system. Currently, the operation to transplant cadaver meniscus relies largely on the natural immuno-privileged status of cartilage for success.

Biological ECM's have been used since the late 1980's, and it is precisely this history that underlies their commerciality and the increase in their use.

[multibagger] 02/1/2016 08:35

O/T

Hi Bamboo2,

I agree that the time scales in the BBC article are too optimistic, but as I have been saying for a long time, before TRX gains commercial traction with its products, technology will have moved on and not enough is being done in R&D IMHO. This is one of the reasons I sold out.

I hope you took some CRX at the 60p range when I mentioned it on this board (post 1469) on 23rd Oct 2015@0802. CRX now knocking on at about 120p having touched 130p recently. But time to take some profits IMHO in CRX.

Still holding AXA Framlington Biotech funds though to retain exposure to biotech/healthcare which has a very strong long term growth trend.

Good luck all :)

[bamboo2] 01/1/2016 12:02

Cheers mb. I read the article and think that the process has potential. I can't agree with their timescale though, it's probably going to take 10 or more years, to go through safety testing and evaluation etc.

[multibagger] 01/1/2016 10:47

Happy New Year all :)

[bamboo2] 31/12/2015 12:18

Ray, At the end of the day/month/year/etc, one of the main reasons most people are here is to show a profit. They could be numerous reasons for NFU raising some cash for their fund. eg to meet some outgoings/make the end of year figures look better/tax.


Those with larger holdings are in a very different position to us PI's, and will sometimes adjust holdings when the chance arises, for example, if there is a buyer around. It doesn't neccesarily mean that they think the prospects for TRX are weak.

Happy New Year. This one is pivotal!

[luminoso] 28/12/2015 15:31

Talking of NFU selling, its worth reflecting on Richard Griffiths' trading again.
A little over a year ago he was selling his TRX holding around 20p, IIRC. At the same time he was putting a similar amount into Aureus Mining at 16p ish. Recently he was averaging down his AUE holding at 5p. They don't always get it right, these multi millionaires and Institutions !

[rayrac] 24/12/2015 14:17

Why bam? But it's good to look at the chart for a change...looks extremely hopeful!

Happy Christmas

[bamboo2] 23/12/2015 22:33

Some late trades reported at 15p. 1.85m shares.

It's good to see NFU taking a profit.

[bamboo2] 23/12/2015 17:31

NFU now hold less than 4%.
with 28,844,099 or 3.795%.

Their original holding was previously diluted down from 4.939% to 4.25%. It was purchased at approx 9p in July '13.

[rayrac] 23/12/2015 13:22

I'm surprised. I didn't think it would be that high!😎

[igbertsponk] 22/12/2015 10:17

Yes, many thanks for that, nice to have the instant market cap figure.
Seems far too small !

[luminoso] 22/12/2015 09:39

Thanks, Bamboo, for the addition to the header.

[melodrama] 22/12/2015 09:24

Back in after selling late last year. Not my 900k i hasten to add!

[rayrac] 22/12/2015 08:44

A 900,000 trade! Now that could be interesting....